Page 78 - Genentech News Today

In pivotal Phase III trials, remibrutinib – a highly selective, oral Bruton’s tyrosine kinase inhibitor – demonstrated clinically meaningful and statistically significant reduction in urticaria...

Entered into a collaboration with Tempus giving Recursion access to over 20 petabytes of multimodal oncology data for the purpose of training causal AI models together with Recursion’s proprietary...

Operator: Good afternoon and thank you for standing by. Welcome to Xencor’s Third Quarter 2023 Conference Call. Please be advised that this call is going to be recorded at the company’s request.

Bayer CEO Bill Anderson, who has been in office since June, wants to press ahead quickly with the announced streamlining of the management team. There are still twelve layers between me and our...

Bayer's new CEO Bill Anderson outlines plans to turn the pharma firm around after stating he is "not happy" with its performance

- Accomplished biotechnology and pharmaceutical executive with over three decades of experience to join Immunome’s Board of Directors - ...

Celldex drug barzolvolimab has mid-stage results in a chronic inflammatory skin disease that top those of an approved Genentech drug and two experimental Novartis therapies. The biotech is preparing to advance its drug to Phase 3 testing in 2024.

Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical and has been in discussions with the biotechnology company for months about its future, according to two...

Victoria Meissner: Thank you. Good morning and afternoon. Thank you for joining us today for BioNTechs Third Quarter 2023 Earnings Call.

​​​​​​​On October 26, 2023, Genentech, a member of the Roche Group, announced that the FDA approved VABYSMO (faricimab-svoa) for the treatment of macular edema following retinal vein...